Atai Life Sciences plans to merge with psychedelic startup Beckley Psytech
Public Health,Health,Psychedelics,Business
Atai Life Sciences, among the most prominent biotechs focused on psychedelic medicines, said Monday it will merge with private psychedelic startup Beckley Psytech, pending results of a trial for a drug based on the practice of “smoking toad.” The new company will be known as Atai Beckley, with Beckley Psytech shareholders receiving 31% of shares in the entity. The deal, which values Beckley at $370 million, comes as the Trump Administration has expressed support for the field. Beckley’s lead program is a synthetic, intranasal form of 5-meo-dmt, a toxin found...
Related Coverage
AllSides Picks
Headline Roundup
FAA Halts Every Flight Nationwide
November 13th, 2026
Headline Roundup
Could There Be More Behind Jensen Huang's Resignation Than Extramarital Affairs?
November 15th, 2026
Headline Roundup
Trump, Putin and Xi Plan Historic Three-Way Summit in China
November 14th, 2026
The Insight
Is America’s homelessness crisis improving?
AllSides Staff
November 13th, 2026